129 related articles for article (PubMed ID: 2495219)
41. Hemostatic/fibrinolytic predictors of allograft coronary artery disease after cardiac transplantation.
Meckel CR; Anderson TJ; Mudge GH; Mitchell RN; Yeung AC; Selwyn AP; Ganz P; Simon DI
Vasc Med; 1997 Nov; 2(4):306-12. PubMed ID: 9575604
[TBL] [Abstract][Full Text] [Related]
42. Alterations in the fibrinolytic system components during acute myocardial infarction.
Ioannidou-Papayannaki E; Lefkos N; Boudonas G; Efthimiadis A; Psirropoulos D; Vogas V; Papadopoulos I; Klonizakis I
Acta Cardiol; 2000 Aug; 55(4):247-53. PubMed ID: 11041123
[TBL] [Abstract][Full Text] [Related]
43. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
44. Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis.
Huber K; Resch I; Stefenelli T; Lang I; Probst P; Kaindl F; Binder BR
Thromb Haemost; 1990 Jun; 63(3):336-9. PubMed ID: 2119522
[TBL] [Abstract][Full Text] [Related]
45. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
Vukovich T; Proidl S; Knöbl P; Teufelsbauer H; Schnack C; Schernthaner G
Thromb Haemost; 1992 Sep; 68(3):253-6. PubMed ID: 1440487
[TBL] [Abstract][Full Text] [Related]
46. Reduced levels of tissue plasminogen activator and plasminogen activator inhibitor in plasma of patients with familial amyloidotic polyneuropathy.
Olofsson BO; Nilsson TK
Haemostasis; 1990; 20(1):31-6. PubMed ID: 2108913
[TBL] [Abstract][Full Text] [Related]
47. Role of fibrinolytic parameters and plasminogen activator inhibitor 1 (PAI-1) promoter polymorphism on premature atherosclerosis in SLE patients.
Bicakcigil M; Tasan D; Tasdelen N; Mutlu N; Yavuz S
Lupus; 2011 Oct; 20(10):1063-71. PubMed ID: 21719525
[TBL] [Abstract][Full Text] [Related]
48. [Effects of guan-mai-shu on tissue-type plasminogen activator and plasminogen activator inhibitor in the plasma of patients with coronary heart disease].
Xiong XZ; Mo SS
Zhongguo Zhong Xi Yi Jie He Za Zhi; 1993 Dec; 13(12):727-9, 708-9. PubMed ID: 8136646
[TBL] [Abstract][Full Text] [Related]
49. Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
Walter T; Szabo S; Kazmaier S; Suselbeck T; Borggrefe M; Hoffmeister HM
Thorac Cardiovasc Surg; 2009 Sep; 57(6):368-71. PubMed ID: 19707983
[TBL] [Abstract][Full Text] [Related]
50. Impact of diabetes-associated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells.
Ren S; Lee H; Hu L; Lu L; Shen GX
J Clin Endocrinol Metab; 2002 Jan; 87(1):286-91. PubMed ID: 11788661
[TBL] [Abstract][Full Text] [Related]
51. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in diabetic foot syndrome.
Kulwas A; Lisewska B; Jundziłł W; Ruszkowska B; Drewniak W; Ruprecht Z; Gadomska G; Rość D
Adv Med Sci; 2017 Mar; 62(1):87-91. PubMed ID: 28193577
[TBL] [Abstract][Full Text] [Related]
52. Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms.
Lindholt JS; Jørgensen B; Shi GP; Henneberg EW
Eur J Vasc Endovasc Surg; 2003 Jun; 25(6):546-51. PubMed ID: 12787697
[TBL] [Abstract][Full Text] [Related]
53. Tissue plasminogen activator release and plasminogen activator inhibitor levels in coronary artery disease.
Meyers DG; Haire WD; Rasmussen JK; Boyd EJ
Angiology; 1991 Jul; 42(7):561-7. PubMed ID: 1907440
[TBL] [Abstract][Full Text] [Related]
54. Endogenous tissue plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusions.
Terres W; Lund GK; Hübner A; Ehlert A; Reuter H; Hamm CW
Am Heart J; 1995 Oct; 130(4):711-6. PubMed ID: 7572577
[TBL] [Abstract][Full Text] [Related]
55. Tissue plasminogen activator, fibrin D-dimer, and insulin resistance in the relatives of patients with premature coronary artery disease.
Mills JD; Mansfield MW; Grant PJ
Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):704-9. PubMed ID: 11950714
[TBL] [Abstract][Full Text] [Related]
56. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study.
Price JF; Mowbray PI; Lee AJ; Rumley A; Lowe GD; Fowkes FG
Eur Heart J; 1999 Mar; 20(5):344-53. PubMed ID: 10206381
[TBL] [Abstract][Full Text] [Related]
57. Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries.
Verheugt FW; ten Cate JW; Sturk A; Imandt L; Verhorst PM; van Eenige MJ; Verwey W; Roos JP
Am J Cardiol; 1987 May; 59(12):1075-9. PubMed ID: 3107367
[TBL] [Abstract][Full Text] [Related]
58. Interrelation between angiographic severity of coronary artery disease and plasma levels of insulin, C-peptide and plasminogen activator inhibitor-1.
Negri M; Sheiban I; Arigliano PL; Tonni S; Montresor G; Carlini S; Manzato F
Am J Cardiol; 1993 Aug; 72(5):397-401. PubMed ID: 8352181
[TBL] [Abstract][Full Text] [Related]
59. Dietary regulation of fibrinolytic factors.
Mehrabian M; Peter JB; Barnard RJ; Lusis AJ
Atherosclerosis; 1990 Sep; 84(1):25-32. PubMed ID: 2147372
[TBL] [Abstract][Full Text] [Related]
60. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsjö, Sweden.
Sundell IB; Nilsson TK; Rånby M; Hallmans G; Hellsten G
J Clin Epidemiol; 1989; 42(8):719-23. PubMed ID: 2503591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
